Life sciences consultancy plans to expand, add 38 jobs
Indianapolis-based Pearl Pathways, founded by two former Eli Lilly employees, plans to move into new space in March and add the jobs by 2016.
Indianapolis-based Pearl Pathways, founded by two former Eli Lilly employees, plans to move into new space in March and add the jobs by 2016.
I am proud to relate that Pawel Fludzinski, Ph.D. recently published his first crossword puzzle in The New York Times. Pawel has worked at Eli Lilly and Co. for more than 28 years with the last 20 years being in executive level leadership positions. He has a Ph.D. in synthetic organic chemistry, but never mind that: He shares with me a love for construction of crossword puzzles.
Competitive, growing public companies that develop job opportunities and invest in the needs and resources of our community have a long-standing ripple effect.
Frustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create a dedicated funding stream that could total $30 million a year.
The state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation Corridor.
Suzanne Clifford has been named executive vice president of behavioral health at Community Health Network, beginning Feb. 25. She replaces Eric Crouse, who is retiring after nearly 34 years at Community. Clifford most recently has led Inspiring Transformations Inc., an Indianapolis-based consulting firm she founded that focused on the delivery of mental health and substance abuse care. Before that, Clifford was director of the Indiana Division of Mental Health and Addiction, and also served stints at Eli Lilly and Co. and General Motors Corp. She holds a bachelor’s in industrial and systems engineering from The Ohio State University and an MBA from Indiana University.
St. Vincent Health has appointed Dr. Craig Wilson chief medical officer of St. Vincent Medical Center Northeast, which is adding 50 inpatient beds and will change its name to St. Vincent Fishers Hospital on April 8. Wilson will remain executive director of hospitalist services at St. Vincent Indianapolis Hospital. Wilson completed his medical degree at the University of Queensland, Australia.
The Indiana Medical Device Manufacturers Council appointed Peggy Welch as its executive director, effective immediately. Welch was a Democratic state legislator from Bloomington for 14 years and works part time as an oncology nurse at the Indiana University Health Bloomington Hospital.
Dr. Nahid Shahrooz has joined the newly established Franciscan Physician Network Dermatology Specialists. Formerly associated with Shahrooz Dermatology and the Indianapolis Institute for Plastic Surgery, she specializes in the surgical removal of skin tumors, cancers and lesions. Shahrooz earned her medical degree at Mashad Medical School in Iran.
Dr. Janice Bilby has joined Franciscan Physician Network Greenwood Parke Family Medicine. Bilby received her undergraduate degree in biology from Ball State University and her medical degree from the Indiana University School of Medicine.
Indiana University Health Morgan Hospital in Martinsville stopped delivering babies on Friday and instead will direct pregnant women to IU Health Bloomington Hospital, which is a 30-minute drive farther south. In 2012, only 3 percent of deliveries at Bloomington Hospital were for moms from Morgan County. But IU Health made the change because the hospital in Martinsville was delivering only 218 of the 1,200 annual births in Morgan County, according to an evaluation by the American College of Obstetrics and Gynecology. The group recommends a hospital have at least 300 births in order to continue its obstetrics program. The change is also being made because many of the women seeking obstetric services at IU Morgan are high-risk patients and the hospital does not have the facilities to serve them, said Amy Wozniak, IU Health Morgan's director of public relations, in a statement. IU Health Bloomington Hospital delivers about 1,900 babies each year. “We understand this affects our community as well as some IU Health Morgan Hospital employees. We believe, however, that this decision is best for our patients,” said Doug Puckett, CEO of IU Health Morgan Hospital.
Indianapolis-based Hall Render Killian Heath & Lyman PC, the nation’s largest health-care-focused law firm, has officially launched a pharmacy practice. Though the practice area is new, several lawyers within the firm have used their pharmacy-related knowledge and experience to serve clients for several years, said John Hall, the firm’s president and managing partner. The lawyers typically counsel retail and mail-order pharmacies, hospitals and long-term-care providers on a variety of issues: regulatory compliance and enforcement support, development and maintenance of compliance programs, Medicare and Medicaid reimbursement, private-payer reimbursement, fraud and abuse, and litigation. Hall Render’s pharmacy practice is led by Susan Bizzell, a shareholder of the firm, and is the latest addition to the firm's more than 60 health-care-related specialties. The pharmacy practice consists of about 10 lawyers. With 97 local attorneys, Hall Render is ranked as the city’s seventh-largest law firm, according to IBJ’s most recent statistics.
Indianapolis-based Pearl IRB LLC, a life sciences consultancy operating as Pearl Pathways, announced Jan. 29 that it plans to add 38 jobs by 2016 as part of a $355,000 expansion. The company, in Indiana University’s Emerging Tech Center near the Central Canal, will use the investment to lease and equip a 2,000-square-foot facility at 29 E. McCarthy St. Pearl Pathways plans to move in March and is hiring additional regulatory-affairs, quality-compliance and clinical-trial specialists. The Indiana Economic Development Corp. said it will provide Pearl Pathways up to $750,000 in performance-based tax credits and up to $75,000 in training grants based on the company's job-creation plans. Founded in 2010 by former Eli Lilly and Co. employees Diana Caldwell and Gretchen Miller Bowker, Pearl Pathways provides research and product development services for drug, biologic and medical device companies.
Zimmer Holdings Inc. predicted revenue and profit will pick up steam in 2013 after its fourth-quarter profit fell 2 percent due to large accounting charges. The Warsaw-based maker of orthopedic implants said it expects revenue to grow this year 2.5 percent to 4.5 percent, when adjusted for foreign currency fluctuations. It expects earnings per share, excluding special charges, to range between $5.65 and $5.85. Those results would mark growth of 7 percent to 10 percent over last year’s adjusted earnings per share of $5.30. In the fourth quarter, Zimmer’s reduced profits still beat estimates of Wall Street analysts. Zimmer earned $152.8 million, or 88 cents per share, in the quarter. The company took a $96 million charge to write down the value of its U.S. spine business, which it says is pressured by lower utilization and lower prices. Excluding that charge and $69 million in other special charges, Zimmer would have earned $1.51 per share. Analysts expected $1.49, according to a survey by Thomson Reuters. For all of 2012, Zimmer’s profit fell 1 percent, to $755 million, from the previous year. Excluding special charges, the company would have earned $932.5 million, an increase of 3 percent. Revenue totaled $4.47 billion, virtually unchanged. Wall Street analysts have said 2013 could be a “breakout” year for Zimmer, which has suffered through several years of slow growth. However, they also worry the company is more exposed than its peers to changes coming in 2014 from the U.S. Patient Protection & Affordable Care Act. Zimmer shares have risen 23 percent in the past 12 months.
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
House Republican leaders toured an Indianapolis preschool Wednesday, one day before the House Education Committee takes up a proposal to give preschool vouchers to low-income families in a small number of cases.
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
Don Marsh’s testimony on cross-examination Thursday morning revealed a defense strategy to convince jurors that the frequent trips the former CEO took on the company’s dime were more for business than pleasure.
With all the talk about increasing health care costs, the Affordable Care Act and Hoosiers’ poor health standings, now is the time for Indianapolis to be bold and take action.
Indiana University Health Physicians added 39 doctors from the division of gastroenterology and hepatology at the IU School of Medicine. The group was founded in 1958 and is consistently ranked as one of the top 20 programs nationally. IU Health Physicians now employs more than 1,000 doctors. The group, which also includes five nurse practitioners, offers care at IU Health University Hospital, Wishard Health Services and the Richard L. Roudebush VA Medical Center, and will soon expand to IU Health North and IU Health Saxony hospitals. They also see patients in satellite offices in Batesville, Carmel, Greenfield, Greensburg, Lebanon, Martinsville, McCordsville and Zionsville.
Elona Biotechnologies Inc., a drugmaker trying to launch a generic version of insulin, says it has found a solution to its default on more than $8 million in economic development loans and incentives from the city of Greenwood. Elona announced Feb. 6 that it has reached an agreement under which the company will be acquired by a group of private investors. It did not disclose the names of the investors or the amount of financing. "While terms of the transaction are confidential, Elona will receive sufficient funds to correct its default situation with the city of Greenwood, hire management and scientific talent to move the company forward, and proceed with clinical trials to support the registration of its generic human insulin under development for the treatment of diabetes," the company said in a prepared statement. An executive team of pharmaceutical industry veterans with extensive experience will join Elona as staff or consultants, the company said. The company told Greenwood officials of its financial troubles in late January. That information prompted the Greenwood Redevelopment Commission to vote to declare Elona in default on $8.4 million worth of economic development incentives the city approved for the company in 2010. The city loaned $6.4 million to help Elona build a 50,000-square-foot, $28 million insulin production plant in Greenwood and hire 70 workers. The city also gave Elona $1.5 million to help it win approval for its insulin from the U.S. Food and Drug Administration and $500,000 for equipment.
Eli Lilly and Co. said it is halting testing of an experimental drug for rheumatoid arthritis because the studies show the medicine is not effective. The decision to stop testing the therapy, called tabalumab, in rheumatoid arthritis wasn’t based on safety concerns, the Indianapolis-based drugmaker said Feb. 7 in a prepared statement. Lilly said it will continue to develop the drug as a treatment for lupus. In December, Lilly said it was stopping one of three late-stage rheumatoid arthritis studies of tabalumab after it failed to provide a benefit. Lilly then analyzed the other two studies and determined the drug was unlikely to help patients. The setback comes as Lilly, counting on sales of new medicines to revive growth, faces generic competition to schizophrenia drug Zyprexa, which generated $5 billion in annual revenue before losing patent protection in October 2011.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Small not-for-profits’ strategy of recruiting big-business executives for top posts has had mixed results since coming into vogue in the 1990s. For some of the executives, the transitions is a culture shock.
Former Amerigroup Corp. CEO Jim Carlson will leave WellPoint Inc., the company told Bloomberg News—three days after he lost a bid for the top job at the Indianapolis-based health insurer. Carlson will leave WellPoint on Feb. 28, according to a statement e-mailed by company spokeswoman Kristin Binns. He had joined the nation's second-largest health insurer in December, after WellPoint closed its $4.9 billion acquisition of Amerigroup. WellPoint named Joe Swedish, CEO of the not-for-profit hospital system Trinity Health Corp., to be its next leader, ending a six-month search. Carlson, 60, was among the other candidates under consideration. “After helping close the Amerigroup transaction and assisting over the past six weeks with the integration of the two companies, Jim Carlson will be leaving WellPoint effective Feb. 28,” WellPoint said in the statement. While Carlson had signed a contract to remain with WellPoint for two years, the pact allowed the two sides to part under “changed circumstances,” said Carl McDonald, a Citigroup analyst, in a Feb. 13 note to clients. The WellPoint statement didn’t mention Carlson’s contract. Binns declined to comment when asked how Carlson’s contract would be handled. WellPoint said last month that Richard Zoretic, Amerigroup’s former chief operating officer, would run its Medicaid business.
In a combative Feb. 13 letter to the Obama administration, Indiana Gov. Mike Pence asked the federal government to approve a three-year extension of the Healthy Indiana Plan health savings accounts in lieu of an expansion of a federal Medicaid system. "Medicaid is broken. It has a well-documented history of substantial waste, fraud and abuse. It has failed to keep pace with private market innovations that have created efficiencies, controlled costs and improved quality," he wrote to U.S. Health and Human Services Secretary Kathleen Sebelius. According to the Associated Press, the Indiana Family and Social Services Administration requested a waiver from the Centers for Medicare and Medicaid Services, seeking to enroll residents who earn up to 138 percent of the federal poverty line in the HIP program — a move that would effectively cover roughly 400,000 residents through health savings accounts instead of traditional Medicaid. The 2010 Patient Protection and Affordable Care Act had called for all states to expand eligibility to the traditional Medicaid program for all residents making up to 138 percent of the federal poverty limit. House Minority Leader Scott Pelath, D-Michigan City, said Pence's move puts thousands of jobs at risks by playing politics with the expansion. It's unclear whether the federal agency in charge of Medicaid will sign off on a longer extension and expansion of the Indiana program. The agency approved a one-year extension last month but ruled out minimum payments. Former Gov. Mitch Daniels sought a three-year extension of the program in 2011, but was rejected.
Bioanalytical Systems Inc. swung to a profit in the quarter ended Dec. 31, the West Lafayatte-based company announced Feb. 14. The company, which conducts preclinical testing for pharmaceutical companies, earned $139,000 during the quarter, or 2 cents per share, compared with a loss in the same quarter a year ago of $1.5 million, or 21 cents per share. But revenue in the quarter fell 23 percent, compared with a year ago, to $5.8 million. Jacqueline Lemke, who was recently named CEO after serving in the role on an interim basis, said in a prepared statement: "With the notable exception of revenue, all of our operating metrics moved decisively in the right direction in the first quarter compared to the prior year. We believe these improvements are sustainable.”
A federal audit recommended that the Indiana Medicaid program refund more than $5.8 million because it failed to ensure that Logansport State Hospital had complied with special conditions for psychiatric hospitals. The audit, released Friday by the Office of Inspector General of the U.S. Department of Health and Human Services, said the hospital failed to demonstrate it met staffing and medical-record requirements from the start of 2008 through the end of 2010. So the inspector general thinks the state of Indiana should refund all federal funds used to pay that hospital during that time period—about $5.84 million—as well as any federal funds paid after 2010 if the hospital continued to be out of compliance. It's unclear whether Indiana will need to refund all the recommended amounts or when that would happen. Audits usually begin a period of negotiations between the two sides. The agency that administers the Indiana Medicaid program, the Family and Social Services Administration, issued a brief statement Friday saying the agency disagrees with the audit findings and plans to work with the federal government to reach "a reasonable resolution."
Dutch diagnostics maker Qiagen NV will work with Eli Lilly and Co. to develop companion tests that could identify patients who could be helped by Lilly's drugs. According to the Associated Press, the companies did not disclose terms of the new collaboration, but described it as a "broad" partnership that will cover "all therapeutic areas." In September 2011, Qiagen started working with Indianapolis-based Lilly on a test designed to identify patients who might be helped by an experimental blood cancer drug. In July 2012, the U.S. Food and Drug Administration approved a genetic test Qiagen developed that is designed to help doctors more quickly determine which late-stage colon cancer patients will respond to the drug Erbitux and which won't benefit from the treatment. Erbitux is marketed by Lilly and Bristol-Myers Squibb Co. In January, Lilly partnered with a unit of Agilent Technologies Inc. to develop a test that can identify cancer patients who could benefit from an experimental cancer drug Lilly is developing.
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.